Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 8/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 8/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 8/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024101 | 0.79 | MAPT (0.49) | PDE1APDE1BPDE1CL3MBTL1POLB | |
| SCHEMBL4020612 | 0.79 | EPHB3 (0.43) | L3MBTL1KDM4EKMT2A | |
| SCHEMBL4023277 | 0.78 | ADRA2B (0.38) | PDE1APDE1BPDE1CL3MBTL1 | |
| SCHEMBL4022131 | 0.75 | MAPT (0.47) | PDE1APDE1BPDE1CL3MBTL1KDM4E | |
| SCHEMBL12859084 | 0.71 | HSD17B10 (0.53) | L3MBTL1POLBKDM4E | |
| SCHEMBL4961331 | 0.69 | L3MBTL1 (0.52) | L3MBTL1POLBKMT2A | |
| SCHEMBL4027817 | 0.69 | L3MBTL1 (0.39) | PDE1APDE1BPDE1CL3MBTL1TACR1 | |
| SCHEMBL2698261 | 0.68 | L3MBTL1 (0.50) | L3MBTL1POLBKMT2A | |
| SCHEMBL11331119 | 0.68 | TRPM5 (0.41) | PDE1APDE1BPDE1CL3MBTL1POLB | |
| SCHEMBL11326396 | 0.68 | LMNA (0.45) | PDE1APDE1BPDE1CL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100503602-C | Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them | DONGBU HANNONG CHEMICAL CO LTD (KR) | 2009-06-24 | — | — | CN | disclosed |
| EP-1499610-B1 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES INCLUDING TETRAZOLE, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HITEK CO LTD (KR) | 2009-01-21 | — | — | EP | disclosed |
| US-7414068-B2 | Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them | DONGBU HANNONG CHEMICAL CO., LTD. (KR) | 2008-08-19 | — | — | US | disclosed |
| EP-1499610-A4 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES INCLUDING TETRAZOLE, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HANNONG CHEMICAL CO LTD (KR) | 2006-05-24 | — | — | EP | disclosed |
| US-20060035948-A1 | Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them | DONGBU HANNONG CHEMICAL CO., LTD. (KR) | 2006-02-16 | — | — | US | disclosed |
| CN-1646524-A | Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them | DONGBU HANNONG CHEMICAL CO LTD (KR) | 2005-07-27 | — | — | CN | disclosed |
| EP-1499610-A2 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES INCLUDING TETRAZOLE, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dongbu Hannong Chemical Co., Ltd. (KR) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003084464-A2 | BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES INCLUDING TETRAZOLE, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DONGBU HANNONG CHEMICAL CO., LTD (KR) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035948-A1 | Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them | TH, TNNI3, NOS3 | PDE1A 2388/4885PDE1B 2615/4885PDE1C 2578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.